Trump got quick access to experimental treatment, but is that ethical?

The special treatment U.S. President Donald Trump received to access an experimental COVID-19 drug raises fairness issues that start with the flawed health care system many Americans endure and end with the public's right to know more about his condition, ethics and medical experts say.